Inactive Instrument

Biocorp

Equities

ALCOR

FR0012788065

Advanced Medical Equipment & Technology

BIOCORP Enters Exclusive Negotiations with SANOFI to Use Their Mallyatm Connected Device with Sanofi’s Integrated Diabetes Care Platform

July 03, 2019 at 02:00 am EDT

BIOCORP announced that they have entered into an exclusive negotiation with SANOFI aimed at introducing their Mallya connected device into SANOFI's integrated diabetes care platform. Under the terms of these exclusive negotiations, BIOCORP will get an initial payment of €4 million from SANOFI to support related development activities.

Latest news about Biocorp

Biocorp: Novo Nordisk exceeds 90% of share capital	23-10-02	CF
Biocorp: Novo Nordisk holds 97.8% of the capital	23-09-29	CF
Biocorp: simplified tender offer opened on September 7	23-09-07	CF
Biocorp: AMF gives go-ahead to proposed simplified tender offer	23-09-06	CF
Biocorp Production Reports Earnings Results for the Half Year Ended June 30, 2023	23-09-04	CI
CAC40: anecdotal rise, caution prevails	23-08-07	CF
CAC40: hovering around 7300 pts, low volumes	23-08-07	CF
CAC40: regains some color and crosses 7300 pts	23-08-07	CF
CAC40: Caution prevails as the week begins with a slight decline	23-08-07	CF
Biocorp: takeover by Novo Nordisk completed	23-08-07	CF
Denmark's Novo Nordisk Closes Biocorp's Controlling Stake Deal	23-08-06	MT
Novo Nordisk A/S (CPSE:NOVO B) completed the acquisition of a 64.4% stake in Biocorp Production from Vatel Capital SAS, Nyenburgh Investment Partners, BIO JAG and Greenstock	23-08-03	CI
Global markets live: Airbus, Intel, Meta Platforms, Berkshire Hathaway...	23-06-19
Biocorp: Novo Nordisk acquires a controlling stake	23-06-19	CF
Novo Nordisk Offers to Buy Biocorp in EUR154 Million Deal	23-06-19	MT
Novo Nordisk A/S (CPSE:NOVO B) agreed to acquire a 64.4% stake in Biocorp Production for €99.1 million.	23-06-18	CI
Pharma giant Novo Nordisk lifts European shares	23-06-06	RE
Global markets live: Walt Disney, Chevron, 3M, Lufthansa, BYD...	23-06-05
Oil Output Cut, Interest Rates in Focus Amid Mixed Exchange-Traded Funds, Equity Futures in Pre-Bell Monday	23-06-05	MT
Novo Nordisk in Talks to Acquire Controlling Stake in Biocorp	23-06-05	MT
Biocorp: exclusive negotiations with Novo Nordisk	23-06-05	CF
Denmark's Novo Nordisk to Buy Controlling Stake in French Delivery Systems Group Biocorp	23-06-05	MT
Novo Nordisk In Talks to Buy Biocorp in EUR154 Million Deal	23-06-05	DJ
Novo Nordisk in talks buy controlling stake in Biocorp	23-06-05	RE
Novo Nordisk Enters into Exclusive Negotiations to Acquire A Controlling Stake in Bicorp, to Be Followed by A Tender Offer on All Remaining Shares	23-06-05	CI

Chart Biocorp

Duration

Period

More charts

Company Profile

Biocorp specializes in the development and manufacture of medical devices and drug delivery systems. The company offers traditional delivery systems, connected injection systems and monitoring devices. Net sales break down by source of income between sales of services (86.9%) and products (13.1%). At the end of 2022, Biocorp has a production site located in France. France accounts for 62.6% of net sales.

Sector

Advanced Medical Equipment & Technology

Calendar

2024-09-25 - Q2 2024 Earnings Release (Projected)

More about the company

Sector Other Advanced Medical Equipment & Technology

	1st Jan change	Capi.
THERMO FISHER SCIENTIFIC	+8.07%	218B
DANAHER CORPORATION	+6.59%	182B
INTUITIVE SURGICAL, INC.	+11.26%	132B
BOSTON SCIENTIFIC CORPORATION	+26.57%	108B
EDWARDS LIFESCIENCES CORPORATION	+13.35%	52.98B
SHENZHEN MINDRAY BIO-MEDICAL ELECTRONICS CO., LTD.	-0.62%	47.59B
AGILENT TECHNOLOGIES, INC.	-0.93%	39.96B
GE HEALTHCARE TECHNOLOGIES INC.	+11.54%	39.22B
RESMED, INC.	+26.76%	26.94B

Other Advanced Medical Equipment & Technology